The major factors driving the growth of this market are the rising scope of POCT devices, advancement in technology, increasing incidence of chronic diseases, rising demand for self-testing point-of-care testing devices, decentralized laboratory testing, and technological advancements like microfluidic lab on a chip technology. These factors increase the demand for devices such as blood glucose meter, CRP, HBA1C, Homocystein. On the other hand, high costsare regulatory hurdles that may hinder the growth of the market.
Pune, India -- (SBWIRE) -- 07/06/2018 -- Data Bridge Market Research added new report of Europe Point of Care Testing Market is expected to reach USD 11,682.54 billion by 2024 from USD 6,051.05 billion in 2016, at a CAGR of 8.6% in the forecast period 2017 to 2024. The new market report contains data for historic years 2015, the base year of calculation is 2016 and the forecast period is 2017 to 2024.
Request for Free Sample Report @: http://databridgemarketresearch.com/request-a-sample/?dbmr=europe-poct-device-market
The Europe POCT Device Market is highly concentrated to a few big players and rest to local players who cater to domestic markets only. Roche dominated the Euope POCT device market market accounting for the highest market share in 2016, followed by Siemens and Abbott. Other players in this market include Alere Inc., Becton, Dickinson and Company, Johnson & Johnson Services Inc., PTS Diagnostics, Instrumentation Laboratory, Nova Biomedical, Beckman Coulter, Inc. among others holds 41.1% of the Europe POCT device market in 2016.
Avail 10% Discount on Direct Purchase or kindly send the email at sopan.gedam@databridgemarketresearch.com
Roche Diagnostics Limited :
Founded in 1896 as F. Hoffmann La , a diagnostic division of Hoffmann-La Roche and head quartered in Basel, Switzerlandis focused on oncology, immunology, ophthalmology, infectious diseases, and neuroscience. The company operates through two business segments: Pharmaceuticals and Diagnostics.
Recent Developments:
In August 2016, Roche Diagnostics Ltd., received FDA approval for cobas Influenza A/B & RSV test for the cobasLiat System that differentiates flu and Respiratory Syncytial Virus (RSV) in 20 minutes.
In May 2015, Roche Diagnostics Ltd., received FDA CLIA Waiver for the cobasLiat PCR System and Strep A assay to test Strep A in throat swab specimen.
Siemens AG:
Incorporated in 1847 and headquartered in Munich, Germany specializing in supplier of systems for power generation and transmission, medical diagnosis, infrastructure and industry solutions. Its main focus is on electrification, automation and digitalization. Siemens AG operates in more than 200 countries across United States, Europe, Western Hemisphere, Africa, and Asia-Pacific SA/NV, Beersel (Belgium), ETM professional control GmbH, Eisenstadt (Austria), Siemens Healthcare Diagnostics Products GmbH (Marburg), Linacre Investments (Pty) Ltd., Kenilworth (South Africa), Siemens Healthcare FZ LLC (Dubai).
Recent Developments:
In November, 2016, Siemens strengthened its healthcare business through public listing to give more focus and flexibility in pursuing its growth strategy.
In June, 2016, Siemens opened a new headquarter in Munich to enhance its global presence in this market.
Abbott:
Founded in 1888 and headquartered in Lake Bluff, Illinois, U.S., Abbott manufactures pharmaceuticals, molecular diagnostics, diabetes care nutritionals, and vascular. The company focused on development and marketing of diagnostics products, medical devices, nutrition and branded generic pharmaceuticals.
Recent Developments:
In May, 2017, Abbott announced CE Mark approval and its use of the new Rx Insertable Cardiac Monitor (ICM), which is the world's first smartphone compatible ICM to identify or detect cardiac arrhythmias, including atrial fibrillation (AF), for therapy.
In May, 2017, Abbott announced the national reimbursement for freestyle Libre in France, providing access to revolutionary technology for people suffering with diabetes. This would help thousands of people to have access to test type 1 and type 2 diabetes.
Inquire more about this report before purchase @ http://databridgemarketresearch.com/inquire-before-buying/?dbmr=europe-poct-device-market
TABLE OF CONTENTS EUROPE POINT OF CARE TESTING MARKET
1. INTRODUCTION
1.1. OBJECTIVES OF THE STUDY
1.2. MARKET DEFINITION
1.3. OVERVIEW OF EUROPE POINT-OF-CARE TESTING MARKET
1.4. CURRENCY AND PRICING
1.5. LIMITATION
1.6. MARKETS COVERED
2. MARKET SEGMENTATION
2.1. MARKETS COVERED
2.2. GEOGRAPHIC SCOPE
2.3. YEARS CONSIDERED FOR THE STUDY
2.4. CURRENCY AND PRICING
2.5. RESEARCH METHODOLOGY
2.6. PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7. SECONDARY SOURCE
2.8. ASSUMPTIONS
3. MARKET OVERVIEW
3.1. DRIVERS
3.1.1. GROWING GERIATRIC POPULATION
3.1.2. ADVANCEMENT IN TECHNOLOGY
3.1.3. DECENTRALIZED LABORATORY TESTING
3.1.4. INCREASED INCIDENCE OF CHRONIC DISEASES
3.1.5. LABORATORY STAFF SHORTAGES
3.2. RESTRAINTS
3.2.1. UNFAVOURABLE REIMBURSEMENT SCENARIO
3.2.2. ECONOMIC COST
3.3. OPPORTUNITIES
3.3.1. EMERGING MICROFLUIDIC LAB-ON-A-CHIP TECHNOLOGY
3.3.2. EMERGING MARKETS
3.3.3. UNMET MEDICAL NEEDS
3.4. CHALLENGES
3.4.1. LACK OF ACCURACY AND EFFICIENCY
3.4.2. DATA MANAGEMENT AND LACK OF CONNECTIVITY
3.4.3. TESTING PERFORMED BY NON-LABORATORY PERSONNEL AND LACK OF AWARENESS AMONG THE USERS
4. EXECUTIVE SUMMARY
5. PREMIUM INSIGHTS
6. EUROPE POINT-OF-CARE TESTING MARKET: REGULATORY SCENARIO
6.1. OVERVIEW:
6.1.1. REGULATORY PROCEDURE:
7. EUROPE POINT-OF-CARE TESTING MARKET: REIMBURSEMENT SCENARIO
7.1. OVERVIEW:
8. EUROPE POINT-OF-CARE TESTING MARKET, BY PRODUCT TYPE
8.1. OVERVIEW
8.2. CARDIOMETABOLIC MONITORING KITS
8.2.1. CARDIAC MARKERS
8.2.2. BLOOD GAS ELECTROLYTE TESTING KITS
8.2.3. HBA1C TESTING KITS
8.2.4. LIPID TESTING KITS
8.3. INFECTIOUS DISEASE TESTING KITS
8.3.1. INFLUENZA TESTING KITS
8.3.2. HIV TESTING KITS
8.3.3. HEPATITIS TESTING KITS
8.3.4. STD TESTING KITS
8.3.5. TROPICAL DISEASESTESTING KITS
8.3.6. HEALTHCARE ASSOCIATED TESTING KITS
8.3.7. RESPIRATORY INFECTIONS TESTING KITS
8.4. CHOLESTEROL TESTING KITS
8.4.1. PROTHROMBIN TIME TESTING KITS
8.4.2. ACTIVATED CLOTTING TIME TESTING KITS
8.5. BLOOD GLUCOSE TESTING KITS
8.6. PREGNANCY AND FERTILITY TESTING KITS
8.7. TUMOR CANCER MARKERS
8.8. URINALYSIS TESTING KITS
8.9. HEMATOLOGY TESTING KITS
8.10. DRUGS OF ABUSE TESTING KITS
8.11. FECAL OCCULT TESTING KITS
8.12. RAPID COAGULATION TESTING KITS
9. EUROPE POINT-OF-CARE TESTING MARKET, BY DISTRIBUTION CHANNEL
9.1. OVERVIEW
9.1.1. DIRECT TENDER
9.1.2. RETAIL PHARMACY
10. EUROPE POINT-OF-CARE TESTING MARKET, BY END USER
10.1. OVERVIEW
10.2. EUROPE POCT MARKET: HOSPITALS
10.3. EUROPE POCT MARKET: CLINICS
10.4. EUROPE POCT MARKET: AMBULATORY CARE
10.5. EUROPE POCT MARKET: HOME HEALTHCARE
10.6. EUROPE POCT MARKET: RESEARCH LABORATORIES
11. EUROPE POINT-OF-CARE TESTING MARKET, BY PRESCRIPTION MODE
11.1. OVERVIEW
11.2. EUROPE POCT MARKET: PRESCRIPTION BASED TESTING KITS
11.3. EUROPE POCT MARKET: OVER THE COUNTER BASED TESTING KITS
12. EUROPE POINT-OF-CARE TESTING MARKET, BY GEOGRAPHY
12.1. OVERVIEW
12.2. EUROPE POINT-OF-CARE TESTING MARKET
12.2.1. GERMANY POINT-OF-CARE TESTING MARKET
12.2.2. FRANCE POINT-OF-CARE TESTING MARKET
12.2.3. U.K. POINT-OF-CARE TESTING MARKET
12.2.4. ITALY POINT-OF-CARE TESTING MARKET
12.2.5. SPAIN POINT-OF-CARE TESTING MARKET
12.2.6. RUSSIA POINT-OF-CARE TESTING MARKET
12.2.7. TURKEY POINT-OF-CARE TESTING MARKET
12.2.8. BELGIUM POINT-OF-CARE TESTING MARKET
12.2.9. NETHERLANDS POINT-OF-CARE TESTING MARKET
12.2.10. SWITZERLAND POINT-OF-CARE TESTING MARKET
12.2.11. REST OF EUROPE POINT-OF-CARE TESTING MARKET
13. EUROPE POINT-OF-CARE TESTING MARKET : COMPANY LANDSCAPE
13.1. COMPANY SHARE ANALYSIS: EUROPE
13.2. COMPANY SHARE ANALYSIS: NORTH AMERICA
13.3. COMPANY SHARE ANALYSIS: EUROPE
13.4. COMPANY SHARE ANALYSIS: APAC
14. COMPANY PROFILES
14.1. JOHNSON AND JOHNSON SERVICES, INC.
14.1.1. COMPANY OVERVIEW
14.1.2. REVENUE ANALYSIS
14.1.3. PRODUCT PORTFOLIO
14.1.4. RECENT DEVELOPMENTS
14.2. BECTON, DICKINSON AND COMPANY
14.2.1. COMPANY OVERVIEW
14.2.2. REVENUE ANALYSIS
14.2.3. PRODUCT PORTFOLIO
14.2.4. RECENT DEVELOPMENTS
14.3. MEDTRONIC
14.3.1. COMPANY OVERVIEW
14.3.2. REVENUE ANALYSIS
14.3.3. PRODUCT PORTFOLIO
14.3.4. RECENT DEVELOPMENTS
14.4. F. HOFFMANN-LA ROCHE LTD
14.4.1. COMPANY OVERVIEW
14.4.2. REVENUE ANALYSIS
14.4.3. PRODUCT PORTFOLIO
14.4.4. RECENT DEVELOPMENTS
14.5. SIEMENS AG
14.5.1. COMPANY OVERVIEW
14.5.2. REVENUE ANALYSIS
14.5.3. PRODUCT PORTFOLIO
14.5.4. RECENT DEVELOPMENTS
14.6. ABBOTT
14.6.1. COMPANY OVERVIEW
14.6.2. REVENUE ANALYSIS
14.6.3. PRODUCT PORTFOLIO
14.6.4. PRODUCT PIPELINE
14.6.5. RECENT DEVELOPMENTS
14.7. DANAHER
14.7.1. COMPANY OVERVIEW
14.7.2. REVENUE ANALYSIS
14.7.3. PRODUCT PORTFOLIO
14.7.4. RECENT DEVELOPMENTS
14.8. WERFENLIFE
14.8.1. COMPANY OVERVIEW
14.8.2. REVENUE ANALYSIS
14.8.3. PRODUCT PORTFOLIO
14.8.4. RECENT DEVELOPMENTS
14.9. HENRY SCHEIN, INC.
14.9.1. COMPANY OVERVIEW
14.9.2. REVENUE ANALYSIS
14.9.3. PRODUCT PORTFOLIO
14.9.4. RECENT DEVELOPMENTS
14.10. OPTI MEDICAL (SUBSIDIARY OF IDEXX LABORATORIES, INC)
14.10.1. COMPANY OVERVIEW
14.10.2. REVENUE ANALYSIS
14.10.3. PRODUCT PORTFOLIO
14.10.4. RECENT DEVELOPMENTS
14.11. SIENCO, INC.
14.11.1. COMPANY OVERVIEW
14.11.2. REVENUE ANALYSIS
14.11.3. PRODUCT PORTFOLIO
14.11.4. RECENT DEVELOPMENTS
14.12. ACON LABORATORIES, INC.
14.12.1. COMPANY OVERVIEW
14.12.2. REVENUE ANALYSIS
14.12.3. PRODUCT PORTFOLIO
14.12.4. RECENT DEVELOPMENTS
14.13. ATIVA MEDICAL CORPORATION
14.13.1. COMPANY OVERVIEW
14.13.2. REVENUE ANALYSIS
14.13.3. PRODUCT PORTFOLIO
14.13.4. RECENT DEVELOPMENTS
14.14. ABAXIS
14.14.1. COMPANY OVERVIEW
14.14.2. REVENUE ANALYSIS
14.14.3. PRODUCT PORTFOLIO
14.14.4. RECENT DEVELOPMENTS
14.15. ARKRAY, INC
14.15.1. COMPANY OVERVIEW
14.15.2. REVENUE ANALYSIS
14.15.3. PRODUCT PORTFOLIO
14.15.4. RECENT DEVELOPMENTS
14.16. AERSCHER DIAGNOSTICS, LLC
14.16.1. COMPANY OVERVIEW
14.16.2. REVENUE ANALYSIS
14.16.3. PRODUCT PORTFOLIO
14.16.4. RECENT DEVELOPMENTS
14.17. ARTRON LABORATORIES, INC.
14.17.1. COMPANY OVERVIEW
14.17.2. REVENUE ANALYSIS
14.17.3. PRODUCT PORTFOLIO
14.17.4. RECENT DEVELOPMENTS
14.18. BIOMERIEUX SA
14.18.1. COMPANY OVERVIEW
14.18.2. REVENUE ANALYSIS
14.18.3. PRODUCT PORTFOLIO
14.18.4. RECENT DEVELOPMENTS
14.19. ENTOPSIS
14.19.1. COMPANY OVERVIEW
14.19.2. REVENUE ANALYSIS
14.19.3. PRODUCT PORTFOLIO
14.19.4. RECENT DEVELOPMENTS
14.20. LIFESIGN, LLC.
14.20.1. COMPANY OVERVIEW
14.20.2. REVENUE ANALYSIS
14.20.3. PRODUCT PORTFOLIO
14.20.4. RECENT DEVELOPMENTS
15. RELATED REPORTS
Purchase Full Report @ http://databridgemarketresearch.com/reports/europe-poct-device-market/
Related Report
Global Transfection Reagents and Equipment Market – Industry Trends and Forecast to 2024
Global Transfection Reagents and Equipment Market By Product Type (Reagents, Equipments), By Method (Biochemical (Lipofection, Calcium Phosphate, Deae-dextran, Dendrimers), Physical (Electroporation, Nucleofection, Sonoporation, Genegun, Magnetofection, Optoinjection), Viral (Adenoviruses, Retroviruses, Adenoassociated viruses)), By Application (Biomedical Research (Gene Expression Studies, Cancer Research, Transgenic Models), Protein Production, Therapeutic Deliver), By End User (Pharmaceutical & Biotechnology Companies, Academics, Research Laboratories) By Geography (North America, Europe, Asia-Pacific, Europe, South America, Middle East and Africa) – Industry Trends and Forecast to 2024
http://databridgemarketresearch.com/reports/global-transfection-reagents-and-equipment-market/
About Data Bridge Market Research
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.
Contact:
Data Bridge Market Research
Tel: +1-888-387-2818
Email: sopan.gedam@databridgemarketresearch.com